Glaucoma scales fail to impress

Article

The Visual Impairment Instrument (IVI) and the Glaucoma Symptom Scale (GSS) are suboptimal scales for assessing patients with glaucoma but relatively good vision.

The Visual Impairment Instrument (IVI) and the Glaucoma Symptom Scale (GSS) are suboptimal scales for assessing patients with glaucoma but relatively good vision, according to a report published in the August issue of Optometry & Vision Science.

Ecosse Lamoureux and colleagues from the University of Melbourne, Australia recruited glaucoma patients from private and public clinics to complete the IVI and GSS questionnaires. The two scales were assessed for fit to the Rasch model; specifically they were assessed for unidimensionality, individual item and person fit to the model, response category performance, differential item functioning and targeting of items to patients.

A total of 175 subjects were recruited, the majority of whom (65%) had primary open-angle glaucoma (POAG) and a visual acuity ≥6/9 in the better eye (87%). Only one third of the subjects had severe visual field loss in both eyes. Disordered thresholds were evident across all GSS items, indicating that the categories were difficult to discriminate and required category collapsing (five to three categories). Both scales demonstrated ineffective person-item targeting.

The authors believe that both IVI and GSS are ineffective scales for assessing glaucomatous patients who have good visual acuity.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.